Revenue and Profitability - Total revenues increased by $3.6 million, or 13%, to $32.1 million for the three months ended March 31, 2024, compared to $28.5 million for the same period in 2023[121] - Product revenue was $19.7 million, consisting of instrument sales of $2.6 million and consumables sales of $17.1 million, representing a 2% increase compared to $19.3 million in the prior year[122] - Service revenue increased by $3.4 million, or 39%, to $12.0 million, primarily driven by a $3.2 million increase in Accelerator Laboratory revenue[123] - Gross profit for the three months ended March 31, 2024, was $19.6 million, representing a gross margin of 61%, compared to a gross profit of $16.9 million and a margin of 59% in the prior year[119] - GAAP gross profit for the three months ended March 31, 2024, was $19.6 million, compared to $16.9 million for the same period in 2023[152] - GAAP revenue increased to $32.1 million for the three months ended March 31, 2024, from $28.5 million in the same period in 2023[152] - Non-GAAP gross margin improved to 54.5% for the three months ended March 31, 2024, compared to 53.1% for the same period in 2023[152] Expenses and Losses - Research and development expenses increased by $2.0 million, or 41%, to $6.7 million, primarily due to increased headcount and professional services[127] - Operating expenses rose by $7.2 million, or 28%, to $33.6 million, leading to a loss from operations of $14.0 million for the three months ended March 31, 2024[119] - The net loss for the three months ended March 31, 2024, was $10.1 million, compared to a net loss of $6.1 million for the same period in 2023, reflecting a 65% increase in losses[119] - Selling, general and administrative expenses increased by $5.1 million, or 25%, to $26.0 million for the three months ended March 31, 2024, compared to $20.9 million for the same period in 2023[128] Cash and Investments - As of March 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $301.9 million[115] - As of March 31, 2024, the company had cash and cash equivalents of $45.3 million and $256.6 million in available-for-sale marketable securities[133] - The company expects its cash and marketable securities will be sufficient to meet operating cash requirements for at least 12 months from the date of the report[134] - Net cash used in operating activities was $20.2 million for the three months ended March 31, 2024, compared to $9.5 million for the same period in 2023, reflecting an increase of $10.7 million[142] - Net cash used in investing activities was $109.2 million during the three months ended March 31, 2024, primarily from the purchase of $137.9 million of marketable securities[144] Future Outlook - The company expects to incur significant expenses and operating losses at least through the next 24 months as it expands sales, marketing, and research efforts[116] - The company is actively assessing potential acquisitions to complement its business and may need to raise additional capital if existing resources are insufficient[136] Regulatory and Product Development - The Lucent AD p-Tau 217 blood test received Breakthrough Device designation from the FDA in March 2024, aimed at aiding in the diagnostic evaluation of Alzheimer's disease risk[117] - Interest income rose by $0.5 million, or 14%, to $3.9 million for the three months ended March 31, 2024, due to higher interest rates on cash and marketable securities[130]

Quanterix Corporation (NASDAQ:QTRX) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Francis Pruell - Investor Relations Masoud Toloue - President and Chief Executive Officer Vandana Sriram - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Kyle Mikson - Canaccord Genuity Sung Ji Nam - Scotiabank Dan Brennan - TD Cowen Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q1 2024 Earnin ...

Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2024 BILLERICA, Mass. – May 7, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024. For additional information on the non-GAAP financial measures included in this press release, please see "Use of Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Measures ...

Quanterix Corporation (NASDAQ:QTRX) Q4 2023 Results Conference Call February 29, 2024 4:30 PM ET Company Participants Vandana Sriram - CFO Masoud Toloue - President and CEO Conference Call Participants Matt Sykes - Goldman Sachs Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Sung Ji Nam - Scotiabank Operator Good day, and thank you for standing by. Welcome to the Quanterix Corporation Q4 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speak ...

Financial Performance - Total revenues for Quanterix Corporation were $122.4 million in 2023, up from $105.5 million in 2022, representing a growth of approximately 16.5%[275] - The company incurred a net loss of $32.3 million in 2023, compared to a net loss of $96.7 million in 2022, indicating a significant reduction in losses[275] - Total revenues increased by $16.8 million, or 16%, to $122.4 million for the year ended December 31, 2023, compared to $105.5 million for 2022[302] - Product revenue was $79.5 million, consisting of instrument sales of $15.7 million and consumables sales of $63.8 million, representing a 14% increase from $69.8 million in 2022[303] - Service revenue increased by $5.8 million, or 17%, to $40.3 million, primarily due to a $9.0 million increase in Accelerator Laboratory revenue[304] - Gross profit rose to $70.6 million, a 51% increase from $46.8 million in 2022, resulting in a gross margin of 58%[307] - Total costs of goods sold and services decreased by $7.0 million, or 12%, to $51.7 million, with cost of product revenue down by 20% to $32.6 million[307][308] - Interest income increased by $10.7 million, or 209%, to $15.8 million, driven by higher interest rates on cash and marketable securities[316] - Net cash used in operating activities was $18.9 million, an improvement from $48.3 million in 2022[326] - Net cash used in operating activities decreased by $29.4 million to $18.9 million in 2023 from $48.3 million in 2022, primarily due to reduced net loss and improved gross margin[328] - Net cash used in investing activities was $148.4 million in 2023, consisting of $175.6 million in marketable securities purchases and $3.8 million in property and equipment purchases[330] - Financing activities provided $2.7 million in cash during 2023, an increase from $2.3 million in 2022, from sales of common stock and exercise of options[332] - GAAP gross profit increased to $70.646 million in 2023 from $46.806 million in 2022, with GAAP gross margin rising to 57.7% from 44.4%[360] - Non-GAAP gross profit for 2023 was $62.5 million, up from $39.595 million in 2022, with non-GAAP gross margin improving to 51.1% from 37.5%[360] - Total operating expenses decreased to $120.347 million in 2023 from $148.510 million in 2022, reflecting cost management efforts[360] Product Development and Launches - Quanterix launched the LucentAD blood test for Alzheimer's disease in July 2023, with an improved version, LucentAD p-Tau 217, launched in October 2023; however, these tests are not expected to generate material revenues until late 2024 or later[278] - Quanterix completed a restructuring plan in 2022, eliminating 119 positions and launching five new Simoa Advantage PLUS assays, which began shipping in Q1 2024[279] - The company plans to expand its sales and marketing efforts and invest in its diagnostics business, including the launch of additional Laboratory Developed Tests (LDTs)[276] - Research and development expenses are expected to increase as the company focuses on improving existing products and launching new ones, particularly in diagnostics[289] Customer Base and Market Presence - The company has completed over 2,200 projects for more than 480 customers globally using Simoa platforms, showcasing its extensive customer base[273] - Approximately 82% of the HD Instrument installed base were HD-X instruments by the end of 2023, reflecting strong adoption of the upgraded technology[267] - Quanterix's Simoa technology has been cited in over 2,700 scientific publications, indicating significant scientific validation and interest in its applications[265] - Approximately 37% of total revenue in 2023 was generated from customers outside the United States, compared to 38% in 2022[363] Financial Position and Capital Management - As of December 31, 2023, the company had cash and cash equivalents of $174.4 million and $146.9 million in marketable securities[319] - The company is assessing potential acquisitions and may need to raise additional capital if existing resources are insufficient[322] - The company expects to continue incurring additional capital expenditures to support expanding infrastructure and workforce in future periods[329] - The STRATEC Supply Agreement includes a total purchase commitment of $3.7 million, with $1.0 million due within one year from December 31, 2023[337] - Remaining lease payments due within one year total $7.1 million, with additional payments of $14.7 million, $15.5 million, and $15.7 million due in subsequent years[335] Market Risks - The company is exposed to market risks including fluctuations in foreign currency exchange rates and interest rates affecting returns on cash and marketable securities[362] - A hypothetical 10% decrease in overall interest rates would have reduced interest income by approximately $1.3 million for the year ended December 31, 2023[368] - The company has not entered into any foreign currency hedging contracts to date, but may consider doing so in the future[364] - A 10% adverse change in foreign exchange rates would decrease potential cash inflows from foreign denominated receivables by $0.8 million[363] - The company’s expenses are primarily denominated in U.S. dollars, with some incurred in Canada, Europe, Japan, and China[363] - The company does not expect its operating results or cash flows to be materially affected by sudden changes in market interest rates[367] - The company has the ability to hold marketable securities until maturity, mitigating potential risks from interest rate fluctuations[367] - Fluctuations in foreign exchange rates could potentially harm the business in the future[363]

Financial Performance - The company reported net losses of $7.8 million and $19.9 million for the three and nine months ended September 30, 2023, respectively, compared to $35.1 million and $78.1 million for the same periods in 2022[129]. - Total revenues increased by $4.7 million, or 18%, to $31.3 million for the three months ended September 30, 2023, compared to $26.6 million for the same period in 2022[146]. - Total revenues for the nine months ended September 30, 2023, increased by $11.1 million, or 14%, to $90.8 million compared to $79.7 million for the same period in 2022[162]. - Product revenue was $19.7 million, an increase of $2.0 million, or 11%, compared to $17.7 million in the prior year, driven by a $6.1 million increase in sales of consumables[147]. - Service revenue rose to $10.9 million, up $2.6 million, or 31%, primarily due to a $3.3 million increase in Accelerator Laboratory revenue[148]. - Product revenue for the nine months ended September 30, 2023, was $58.6 million, an increase of $5.5 million, or 10%, compared to $53.1 million for the same period in 2022[163]. - Service revenue increased by $4.3 million, or 17%, to $30.1 million for the nine months ended September 30, 2023, driven by higher volumes in sample testing and assay development services[165]. - Collaboration and license revenue rose to $1.2 million, a 158% increase from $0.5 million in the prior year, primarily due to a one-time increase from the Abbott License Agreement[166]. - Grant revenue increased by $0.5 million, or 146%, to $0.9 million for the nine months ended September 30, 2023, attributed to the receipt of a portion of the NIH Grant[167]. Expenses and Cost Management - The company expects to incur significant expenses and operating losses for at least the next 24 months due to expansion in sales, marketing, and research and development efforts[130]. - Total costs of goods sold and services decreased by $2.2 million, or 14%, to $13.6 million for the three months ended September 30, 2023[150]. - Cost of goods sold and services decreased by $8.5 million, or 19%, to $37.0 million for the nine months ended September 30, 2023, compared to $45.5 million in the prior year[168]. - Research and development expenses rose by $0.6 million, or 9%, to $7.2 million, mainly due to professional services fees for product development[153]. - Research and development expenses decreased by $2.4 million, or 12%, to $17.9 million for the nine months ended September 30, 2023, due to reduced headcount from the Restructuring Plan[171]. - Selling, general, and administrative expenses increased by $3.6 million, or 18%, to $23.6 million, attributed to higher professional services and consulting fees[154]. - GAAP total operating expenses decreased to $31,553 million in Q3 2023 from $47,547 million in Q3 2022, a reduction of 33.6%[200]. - Non-GAAP total operating expenses for Q3 2023 were $29,000 million, down from $45,908 million in Q3 2022, a decrease of 36.8%[200]. Profitability and Margins - Gross profit increased by $6.8 million, or 62%, to $17.8 million, representing 57% of total revenues[150]. - GAAP gross profit for Q3 2023 was $17,783 million, up from $10,944 million in Q3 2022, representing a 62.5% increase[200]. - Non-GAAP gross profit for Q3 2023 was $15,230 million, compared to $9,305 million in Q3 2022, reflecting a 63.8% increase[200]. - GAAP gross margin improved to 56.8% in Q3 2023 from 41.1% in Q3 2022[200]. - Non-GAAP gross margin increased to 48.6% in Q3 2023, up from 34.9% in Q3 2022[200]. - GAAP loss from operations for Q3 2023 was $13,770 million, compared to a loss of $36,603 million in Q3 2022, showing an improvement of 62.4%[200]. - Non-GAAP loss from operations remained at $13,770 million for Q3 2023, consistent with the loss reported in Q3 2022[200]. Cash and Investments - As of September 30, 2023, the company had cash, cash equivalents, and marketable securities totaling $327.7 million[129]. - As of September 30, 2023, the company had cash and cash equivalents of $201.3 million and marketable securities of $126.4 million[180]. - Net cash used in operating activities was $12.9 million for the nine months ended September 30, 2023, a reduction of $31.3 million from $44.2 million in the prior year[184]. - Net cash used in investing activities was $126.8 million for the nine months ended September 30, 2023, primarily for the purchase of marketable securities[186]. - Interest income, net increased by $2.5 million, or 144%, to $4.2 million, primarily due to higher interest rates on cash and cash equivalents[157]. - Interest income, net increased by $9.2 million, or 397%, to $11.5 million for the nine months ended September 30, 2023, primarily due to higher interest rates on cash and marketable securities[177]. Strategic Initiatives - In October 2023, the company entered into a license agreement with Janssen Sciences Ireland UC, granting worldwide rights to J&J's p-Tau 217 antibodies for clinical research and diagnostic products[130]. - The company launched Lucent Diagnostics in July 2023, introducing initial blood-based biomarker LDTs for evaluating cognitive symptoms related to Alzheimer's disease[131]. - The NIH Grant awarded the company a total value of $1.7 million for developing point-of-care diagnostic technologies, with $0.5 million received as of September 30, 2023[133]. - The company continues to utilize non-GAAP measures to assess operational performance and progress against the Restructuring Plan[197]. - Approximately 81% of the HD instrument installed base was comprised of HD-X instruments as of September 30, 2023[122]. - The company has completed over 2,200 projects for more than 470 customers globally using its Simoa platforms[127].

Quanterix Corporation (NASDAQ:QTRX) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Ed Joyce - VP, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Jake Allen - Goldman Sachs Dan Brennan - Cowen Puneet Souda - Leerink Partners Operator Good day and thank you for standing by. Welcome to the Quanterix Corporation Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode. After the spea ...

Discovery Fueled by Ultra-Sensitivity Forward-Looking Statements & Non-GAAP Financial Measures 2 The Simoa advantages: ultra sensitivity that enables bloodbased detection in the earliest stages of disease, with a simplified workflow for scaled deployment. Alzheimer's Disease Continuum www.lucentdiagnostics.com Q2 2022 $23.5M $26.6M $25.8M CEO transition on April 25th Business strategic review starting in June $28.5M Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Strategic review completed in July, business ...

Financial Data and Key Metrics Changes - Second quarter revenue increased by 32% to $31 million compared to the same quarter in 2022 [10][21] - Non-GAAP gross margin improved to 56.4% from 29.1% in the prior year [31] - Net loss decreased from $24.9 million in Q2 2022 to $6.1 million in Q2 2023 [32] - Cash burn improved significantly, with the company achieving breakeven cash flow for the quarter [11][33] Business Line Data and Key Metrics Changes - Consumables revenue rose by 65% year-over-year, totaling $6 million [25] - Accelerator Services revenue increased by 23% to $10.6 million, driven by strong demand [26] - Instrument revenue declined by 38% to $3.5 million, reflecting global macroeconomic pressures [30] Market Data and Key Metrics Changes - The company launched LucentAD, a test for Alzheimer's diagnostics, which is expected to enhance screening capabilities [14][15] - The BioHermes clinical trial achieved positive results, supporting the correlation between p-tau181 and amyloid PET scans [19][20] Company Strategy and Development Direction - The company is in the final stages of a corporate transformation aimed at maximizing the potential of its Simoa technology [12] - Plans include launching new assay kit SKUs and implementing modern processes in operations [13] - The focus is on building global infrastructure for Alzheimer's testing and enhancing patient and provider education [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing macroeconomic pressures affecting capital purchases but expressed confidence in offsetting these challenges [49] - The company raised its full-year revenue guidance to a range of $110 million to $116 million [11][34] - Anticipated cash burn for the year is now estimated to be between $30 million and $35 million, a significant improvement from previous guidance [44] Other Important Information - The company is preparing for a leadership transition as the CFO plans to retire in early 2024 [35] - The recent approval of Leqembi for Alzheimer's therapy is expected to drive demand for the LucentAD test [15] Q&A Session Summary Question: What are the expectations for revenue guidance and potential impacts on the second half of the year? - Management indicated that the guidance reflects a conservative approach due to macroeconomic conditions affecting biotech funding [45][48] Question: When will the platform include p-Tau 217 and other markers? - Plans are in place to introduce p-Tau 217 as an LDT this year, with further developments expected [51][52] Question: What is the current level of validation for the assays and their scalability? - The company has robust clinical trial data supporting the assays, and scalability is a key focus for future growth [54][56] Question: Can you provide more details on the Abbott collaboration? - The revenue from Abbott is related to an expired license deal, contributing to one-time revenue this quarter [81] Question: What are the key milestones to watch for Quanterix in the next 12 months? - Key milestones include advancements in multi-marker tests and the adoption of blood biomarkers for diagnosis [102][103]

Q2 2023 Cash *Includes Lilly MCA revenue in FY2022 and YTD2023 Q2 2023 Earnings To supplement Quanterix's financial statements presented on a GAAP basis, Quanterix has provided certain non-GAAP financial measures. Management uses these non-GAAP measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and as a factor in assessing progress against the Restructuring Plan. Management believes that presentation of the ...